SCM
ELTX icon

Stonepine Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Stonepine Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,018
Closed -$2.74M – 25
2021
Q3 		$2.74M Buy
28,018
+5,734
+26% +$620K 1.25% 17
2021
Q2 		$2.9M Buy
22,284
+8,786
+65% +$1.27M 1.52% 16
2021
Q1 		$2.44M Buy
+13,498
New +$2.61M 1.32% 19

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stonepine Capital Management's ELTX Position: Q4 2021 in Review

Stonepine Capital Management sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 28,018 shares — an estimated $2.74M sold.

Stonepine Capital Management first reported a position in ELTX in Q1 2021 and held it in 3 quarters. The position peaked at $2.9M in Q2 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

  • Stonepine Capital Management reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Stonepine Capital Management sold 28,018 Elicio Therapeutics shares in Q4 2021, an estimated $2.74M.
  • Stonepine Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and held it in 3 quarters.
  • Stonepine Capital Management's Elicio Therapeutics position peaked at $2.9M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.